Диссертация (1155054), страница 32
Текст из файла (страница 32)
– 2008. –Vol. 5. – № 4. – P. 505-515 doi:10.1021/mp800051m.93. Farokhzad O.C. Impact of Nanotechnology on Drug Delivery / O.C. Farokhzad, R.Langer // ACS Nano. – 2009. – Vol. 3. – № 1. – P. 16-20 doi:10.1021/nn900002m.94. Fatality involving vinblastine overdose as a result of a complex medical error / M.Kłys, T. Konopka, M. Scisłowski [et al.] // Cancer chemotherapy and pharmacology. –2007.
– Vol. 59. – № 1. – P. 89-95 doi:10.1007/s00280-006-0246-1.95. FDA Oncologic Drugs Advisory Committee. Marqibo® (Vincristine SulfateLiposomes Injection) for the Treatment of Advanced Relapsed and/or RefractoryPhiladelphia Chromosome Negative (Ph-) Adult Acute Lymphoblastic Leukemia /FDA Oncologic Drugs Advisory Committee // Oncology Drugs Advisory Committee.– 2012. – P. 1-162.19696. Fernandez-Fernandez A.
Theranostic Applications of Nanomaterials in Cancer:Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms / A. FernandezFernandez, R. Manchanda, A.J. McGoron // Applied Biochemistry and Biotechnology.– 2011. – Vol. 165. – P. 1628-1651 doi:10.1007/s12010-011-9383-z.97. Fluorescent vinblastine probes for live cell imaging / L.G. Meimetis, R.J. Giedt, H.Mikula [et al.] // Chemical Communications. – 2016. – Vol.
52. – № 64. – P. 99539956 doi:10.1039/C6CC04129A.98. Folic acid-conjugated liposomal vincristine for multidrug resistant cancer therapy /C. Wang, L. Feng, X. Yang [et al.] // Asian Journal of Pharmaceutical Sciences. –2013. – Vol. 8. – № 2. – P. 118-127 doi:10.1016/j.ajps.2013.07.015.99. Food and Drug Administration. Fosaprepitant - Prescribing Information / Food andDrug Administration. – NJ 08889: MERCK & Co., INC., 2008. – 1-16 p.100. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas /N. Haim, R. Epelbaum, M. Ben-Shahar [et al.] // Cancer. – 1994. – Vol.
73. – № 10. –P. 2515-2519doi:10.1002/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G.101. Gardeck A.M. Immune and viral therapies for malignant primary brain tumors /A.M. Gardeck, J. Sheehan, W.C. Low // Expert Opinion on Biological Therapy. –2017. – Vol. 17. – № 4. – P. 457-474 doi:10.1080/14712598.2017.1296132.102. Garratty G. Modulating the red cell membrane to produce universal/stealth donorred cells suitable for transfusion / G. Garratty // Vox Sanguinis.
– 2007. – Vol. 94. –№ 2. – P. 87-95. doi:10.1111/j.1423-0410.2007.01003.x.103. Ghosh J.S. Antimicrobial Activity of Catharanthus roseus – A Detailed Study /J.S. Ghosh, P.J. Patil // British Journal of Pharmacology and Toxicology. – 2010. –Vol. 1. – № 1. – P. 40-44.104. Godfrin Y. Erythrocytes as a drug delivery system / Y. Godfrin // Innovations inPharmaceutical Technology.
– 2009. – № 28. – P. 60-62.197105. Goswami S. Preliminary Phytochemical Screening and Standardisation of Leavesof Catharanthus Roseus ( L .) G . Don / S. Goswami. – 2009. – Vol. 1. – № 1. – P. 2124.106. Gottlieb R.J. Vincristine-induced bladder atony / R.J. Gottlieb, J. Cuttner //Cancer.–1971.–Vol. 28.–№ 3.–P.
674-675doi:10.1002/1097-0142(197109)28:3<674::AID-CNCR2820280323>3.0.CO;2-J.107. Grobmyer S.R. Cancer Nanotechnology: Methods and Protocols : Methods inMolecular Biology. Vol. 624 / S.R. Grobmyer, B.M. Moudgil; eds. S.R. Grobmyer,B.M. Moudgil. – Totowa, NJ: Humana Press, 2010. – 396 p. doi:10.1007/978-160761-609-2.108.
Guo X. Steric Stabilization of Fusogenic Liposomes by a Low-pH Sensitive PEGDiortho Ester-Lipid Conjugate / X. Guo, F.C. Szoka // Bioconjugate Chemistry. –2001. – Vol. 12. – № 2. – P. 291-300 doi:10.1021/bc000110v.109. Halahakoon A.J. Validated spectrophotometric method for the estimation ofvincristine and vinblastine / A.J. Halahakoon, S.A.
Ivanovich, K.P. Mihailovich //International Journal of Pharmacy and Pharmaceutical Sciences. – 2017. – Vol. 9. –№ 4. – P. 78 doi:10.22159/ijpps.2017v9i4.16577.110. He R. Trimethyl chitosan based conjugates for oral and intravenous delivery ofpaclitaxel / R. He, C. Yin // Acta Biomaterialia.
– 2017. – Vol. 53. – № February. –P. 355-366 doi:10.1016/j.actbio.2017.02.012.111. Hisiger S. Analysis of Catharanthus roseus alkaloids by HPLC / S. Hisiger, M.Jolicoeur // Phytochemistry Reviews. – 2007. – Vol. 6. – № 2-3. – P. 207-234doi:10.1007/s11101-006-9036-y.112. Hoffman A.S.
The origins and evolution of "controlled" drug delivery systems /A.S. Hoffman // Journal of Controlled Release. – 2008. – Vol. 132. – № 3. – P. 153163 doi:10.1016/j.jconrel.2008.08.012.113. HPLC-CD On-Line Coupling in Combination with HPLC-NMR and HPLC198MS/MS for the Determination of the Full Absolute Stereostructure of New Metabolitesin Plant Extracts / G. Bringmann, K. Messer, M. Wohlfarth [et al.] // AnalyticalChemistry. – 1999.
– Vol. 71. – № 14. – P. 2678-2686 doi:10.1021/ac990001d.114. Hu C.M.J. Erythrocyte-inspired delivery systems / C.M.J. Hu, R.H. Fang, L.Zhang // Advanced Healthcare Materials. – 2012. – Vol. 1. – № 5. – P. 537-547doi:10.1002/adhm.201200138.115. Human Erythrocytes Covered with Magnetic Core-Shell Nanoparticles forMultimodal Imaging / M. Laurencin, N. Cam, T. Georgelin [et al.] // AdvancedHealthcareMaterials.–2013.–Vol. 2.–№ 9.–P. 1209-1212doi:10.1002/adhm.201200384.116.
Ibrahim H.Mohammed. Effect of Vincristine and Vinblastine from Vinca Rosa onMicrotubulues of Tumor H22 Cell Line / Ibrahim H.Mohammed // Diyala Journal ofMedicine. – 2012. – Vol. 3. – № 1. – P. 97-104.117. Identification, characterization and distribution of terpene indole alkaloids inethanolicextractsofCatharanthusroseususinghigh-performanceliquidchromatography/electrospray ionization quadrupole time-of-flight tandem massspectrometry and the stud / S. Kumar, V. Bajpai, A. Singh [et al.] // RapidCommunications in Mass Spectrometry. – 2018.
– Vol. 32. – № 4. – P. 319-332doi:10.1002/rcm.8037.118. Ihler G.M. Enzyme Loading of Erythrocytes / G.M. Ihler, R.H. Glew, F.W.Schnure // Proceedings of the National Academy of Sciences. – 1973. – Vol. 70. –№ 9. – P. 2663-2666 doi:10.1073/pnas.70.9.2663.119. Ihler G.M. Hypotonic hemolysis methods for entrapment of agents in resealederythrocytes / G.M. Ihler, H.C. Tsang // Methods in enzymology. – 1987. – Vol. 149. –P. 221-9.120. Immordino M.L.
Stealth Liposomes : Review of the Basic Science , Rationale ,and Clinical Applications , Existing and Potential Stealth liposomes : review of thebasic science , rationale , and clinical applications , existing and potential / M.L.199Immordino, L. Cattel. – 2016. – № April. – P. 297-315.121.
Improved brain delivery of vincristine using dextran sulfate complex solid lipidnanoparticles: Optimization and in vivo evaluation / E. Aboutaleb, F. Atyabi, M.R.Khoshayand [et al.] // Journal of Biomedical Materials Research Part A. – 2014. –Vol. 102. – № 7. – P. 2125-2136 doi:10.1002/jbm.a.34890.122. In vivo administration of liposomal vincristine sensitizes drug-resistant humansolid tumors / C. Leonetti, M. Scarsella, S.C.
Semple [et al.] // International Journal ofCancer. – 2004. – Vol. 110. – № 5. – P. 767-774 doi:10.1002/ijc.20174.123. Increased risk of vincristine neurotoxicity associated with low CYP3A5expression genotype in children with acute lymphoblastic leukemia / A. Egbelakin,M.J. Ferguson, E.A. MacGill [et al.] // Pediatric Blood & Cancer. – 2011. – Vol. 56. –№ 3. – P. 361-367 doi:10.1002/pbc.22845.124. Intravenous vincristine infusion: Phase I trial / D.
V. Jackson, V.S. Sethi, C.L.Spurr [et al.] // Cancer. – 1981. – Vol. 48. – № 12. – P. 2559-2564 doi:10.1002/10970142(19811215)48:12<2559::AID-CNCR2820481203>3.0.CO;2-6.125. Invitro antibacterial activity of methanolic leaf extract derived from Catharanthusroseus / K.
Dharmalingam, M.K. Yogeswari, K.S. Yoha [et al.] // International Journalof Life Science & Pharma Research. – 2015. – Vol. 5. – № 2. – P. 72-77.126. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: druginteractions / X.R. Zhou-Pan, E. Seree, X.J. Zhou [et al.] // Cancer Res. – 1993. –Vol. 53. – № 21. – P. 5121-5126.127.
Jakovljevic I.M. Colorimetric Method for the Determination of Vinblastine, anAlkaloid from Vinca rosea I / I.M. Jakovljevic // Journal of Pharmaceutical Sciences. –1962. – Vol. 51. – № 2. – P. 187-188 doi:10.1002/jps.2600510226.128. Jakovljevic I.M. Assay Methods for Some Vinca rosea Alkaloids II / I.M.Jakovljevic, L. David Seay, R.W. Shaffer // Journal of Pharmaceutical Sciences.
–1964. – Vol. 53. – № 5. – P. 553-557 doi:10.1002/jps.2600530521.200129. Jangde R. An Overview of Resealed Erythrocyte for Cancer Therapy / R. Jangde// Asian J. Res. Pharm. Sci. – 2011. – Vol. 1. – № 4. – P. 83-92.130. Jeong W.T. A UPLC-ESI-Q-TOF method for rapid and reliable identification andquantification of major indole alkaloids in Catharanthus roseus / W.T. Jeong, H. BinLim // Journal of Chromatography B. – 2018. – Vol.
1080. – P. 27-36doi:10.1016/j.jchromb.2018.02.018.131. Jordan M.A. Mechanism of Inhibition of Cell Proliferation by Vinca Alkaloids1 /M.A. Jordan, D. Thrower, L. Wilson // Cancer Research. – 1991. – Vol. 51. – P. 22122222.132. Jordan M.A. Microtubules and actin filaments: dynamic targets for cancerchemotherapy / M.A. Jordan, L. Wilson // Current Opinion in Cell Biology. – 1998. –Vol. 10.
– № 1. – P. 123-130 doi:10.1016/S0955-0674(98)80095-1.133. Jossang A. A New Structural Class of Bisindole Alkaloids from the Seeds ofCatharanthus roseus : Vingramine and Methylvingramine / A. Jossang, P. Fodor, B.Bodo // The Journal of Organic Chemistry. – 1998. – Vol. 63. – № 21. – P. 7162-7167doi:10.1021/jo972333t.134.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
